Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
Podcasts
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 76, Issue 6
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Clinical and epidemiological research
Extended report
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Online download statistics by month:
Online download statistics by month: February 2017 to February 2024
Abstract
Full
Pdf
Feb 2017
10
174
420
Mar 2017
11
916
405
Apr 2017
2
438
111
May 2017
0
577
205
Jun 2017
69
302
120
Jul 2017
246
247
105
Aug 2017
208
209
84
Sep 2017
211
211
101
Oct 2017
256
256
85
Nov 2017
243
243
52
Dec 2017
350
350
54
Jan 2018
392
393
75
Feb 2018
279
268
46
Mar 2018
311
305
53
Apr 2018
409
412
54
May 2018
205
206
47
Jun 2018
188
190
37
Jul 2018
158
158
45
Aug 2018
280
280
58
Sep 2018
189
189
54
Oct 2018
235
235
93
Nov 2018
252
261
62
Dec 2018
190
191
42
Jan 2019
209
211
48
Feb 2019
254
258
71
Mar 2019
163
163
57
Apr 2019
170
170
45
May 2019
143
140
48
Jun 2019
137
137
56
Jul 2019
135
125
49
Aug 2019
152
147
46
Sep 2019
128
121
35
Oct 2019
162
145
57
Nov 2019
109
105
30
Dec 2019
128
120
43
Jan 2020
108
106
47
Feb 2020
116
110
44
Mar 2020
152
147
46
Apr 2020
157
150
71
May 2020
95
86
39
Jun 2020
135
130
57
Jul 2020
108
96
40
Aug 2020
69
67
84
Sep 2020
69
67
36
Oct 2020
303
277
67
Nov 2020
103
91
34
Dec 2020
103
88
39
Jan 2021
85
78
33
Feb 2021
68
63
32
Mar 2021
95
90
30
Apr 2021
95
92
38
May 2021
108
87
40
Jun 2021
118
112
33
Jul 2021
51
51
37
Aug 2021
58
55
31
Sep 2021
88
84
30
Oct 2021
106
103
42
Nov 2021
83
78
55
Dec 2021
72
74
21
Jan 2022
137
142
51
Feb 2022
78
77
29
Mar 2022
74
74
26
Apr 2022
111
107
40
May 2022
97
93
48
Jun 2022
94
95
33
Jul 2022
90
89
31
Aug 2022
121
116
35
Sep 2022
99
96
33
Oct 2022
93
91
29
Nov 2022
74
70
34
Dec 2022
87
78
29
Jan 2023
101
100
28
Feb 2023
87
84
14
Mar 2023
107
104
25
Apr 2023
69
62
19
May 2023
49
46
28
Jun 2023
47
46
14
Jul 2023
58
55
24
Aug 2023
58
51
30
Sep 2023
83
78
54
Oct 2023
189
186
30
Nov 2023
332
327
23
Dec 2023
117
108
73
Jan 2024
87
72
254
Feb 2024
108
99
19
Total
11776
13781
5072
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?